Compare Recursion Pharmaceuticals Inc (RXRX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Under Armour Inc Class A — how do they compare? Recursion Pharmaceuticals Inc trades at $4.25 (market cap $2.14B), while Under Armour Inc Class A trades at $4.96 (market cap $2.07B). The key difference: Recursion Pharmaceuticals Inc and Under Armour Inc Class A are close in size by market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| RXRX | UAA | |
|---|---|---|
Market Cap | $2.14B | $2.07B |
Volume | 30,789,535 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $8.14 |
52-Week Low | $2.84 | $4.17 |
Typical Hold Time | 23 Days | — |
Enterprise Value | $1.66B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Under Armour (UAA) trades at $4.94, up 2.49% today, as the company navigates a challenging turnaround. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing, while technical indicators show a bullish trend despite negative profitability metrics. The company faces revenue declines but maintains margin improvement focus, with analyst consensus leaning toward Hold amid ongoing transformation efforts.
The outlook remains cautious with revenue weakness offset by cost discipline. Investment opportunity exists if margin gains translate to sustained profitability, but risks include persistent demand softness and high debt levels. Current valuation appears reasonable with P/S of 0.42, though negative ROE and net margins warrant careful monitoring of the brand transformation progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
